Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACTION Trial: Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I).

NCT03334305 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03334305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03334305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACTION Trial: Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I).
Lead sponsor
University of Florida
Phase
Phase 1
Overall status
Terminated
Start date
August 27, 2018
Completion date
March 20, 2025
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

high grade glioma, malignant glioma